Erasca, Inc. Common Stock

Erasca trades at a $3.1B valuation despite posting no profitable earnings, making traditional valuation metrics impossible to assess. The RSI of 36.4 signals oversold conditions after what appears to be a meaningful pullback from 52-week highs, yet the 12.26% short interest suggests persistent skepticism from bearish traders. For a clinical-stage biotech firm, this combination—depressed momentum indicators paired with moderate short positioning—hints at capitulation-driven selling rather than fundamental deterioration. The absence of profitability metrics underscores the binary risk profile typical of early-stage therapeutics, where clinical trial outcomes will ultimately determine valuation justification.